A once great department has fallen far - Mitarbeiter (anonym) bei Merck: Mitarbeiterbewertung

2,0
10. Jan. 2021
Mitarbeiter (anonym)
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

-Colleagues are incredibly talented, professional, hard working, and an all around pleasure to work with. -Management understands the importance of work/life balance. -Salary and benefits are solid. -Having "Merck" on your resume will help you throughout your career. -The day-to-day job is fun and rewarding.

Kontras

Chemistry management simply does not care about discovering drugs. They treat the department like an academic institution by emphasizing visibility, publications, and external presentations above all else. First line management (Directors) are more or less ineffective. They have too many direct reports, and their seldom interaction with them leads to them being out of touch and disconnected from the lab workers. This further leads to year-end reviews that honestly look like they're just guessing. Promotions are inscrutable. Management refuses to provide any clarity to the process. Playing games and politicking helps, but your work certainly doesn't.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle